New peer-reviewed, scientific study shows Vyleesi enhances sexual brain processing in premenopausal women with HSDD. Click here to learn more ›

January 2022

Palatin Announces Presentation at the 2022 Crohn’s and Colitis Congress

Press Releases / By

Pre-clinical data demonstrate positive treatment effects of melanocortins for ulcerative colitis Genomic data characterizing the mechanism of action Jan 21, 2022, 07:30 ET CRANBURY, N.J., Jan. 21, 2022 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, …

Palatin Announces Presentation at the 2022 Crohn’s and Colitis Congress Read More »

Palatin to Present at H.C. Wainwright BioConnect Conference

Press Releases / By

Jan 07, 2022, 10:59 ET CRANBURY, N.J., Jan. 7, 2022 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, announced that the Company will present and host one-on-one meetings at the H.C. Wainwright BioConnect Virtual Conference …

Palatin to Present at H.C. Wainwright BioConnect Conference Read More »

Scroll to Top